AIDS Therapy

Patient enrollment completed in HIV vaccine trial

Published in AIDS Weekly, February 16th, 2004

Epimmune, Inc., (EPMN) announced that it has completed patient enrollment in the phase I/II therapeutic HIV vaccine trial of its EP HIV-1090 vaccine candidate.

All 10 patients in the fourth and final dose group have now received their initial vaccinations. The trial is being conducted at the University of Colorado Health Sciences Center with sponsorship from the National Institutes of Health (NIH).

The phase I/II trial is a double blind, placebo-controlled, dose-escalation study and includes four dose groups of 10 patients each for a total of 40 patients. The primary objective of this study is to determine the safety of the EP HIV-1090 vaccine. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2004-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry